Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)"

Ann Surg. 2019 Aug;270(2):e48-e50. doi: 10.1097/SLA.0000000000003115.

Authors

Zachary R McCaw¹, Lu Tian, Dae Hyun Kim, Lee-Jen Wei

Affiliation

¹ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA Department of Biomedical Data Science, Stanford University School of Medicine, Palo Alto, CA Institute For Aging Research, Hebrew SeniorLife, Boston, MA Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Deoxycytidine / analogs & derivatives
Gemcitabine
Humans
Neoadjuvant Therapy*
Pancreatic Neoplasms*
Prospective Studies

Substances

Deoxycytidine
Gemcitabine

Grants and funding

R01 HL089778/HL/NHLBI NIH HHS/United States